When patients lose weight through GLP-1 therapy, they often experience shifts in their lipid profiles that contribute to better heart health outcomes
The covariates were adjusted in the PSM model for a priori-identified potential confounders, such as age, sex, race/ethnicity, nicotine dependence, BMI, type 2 diabetes, hypertension, hyperlipidaemia, hypercholesterolaemia, chronic respiratory disease, chronic renal diseases, BP, chronic kidney disease, peripheral vascular diseases, diabetes-related microvascular complications, glomerular diseases, cirrhosis of the liver, osteoporosis, sleep apnoea, abnormal laboratory findings (HbA 1c , serum cholesterol, LDL-cholesterol, HDL-cholesterol and triacylglycerol [TG]) and intake of cardiovascular medications (Table 1)
Pre-treatment of neurons with GLP-1 significantly reduced the susceptibility of glutamate-induced neuronal death
La Candelaria Deleg
Increased blood flow means more coherence, which adds up to greater vitality
Our treatments include medically supervised weight loss with GLP-1 medications like Semaglutide and Tirzepatide, testosterone replacement therapy for men and women experiencing low T, bioidentical hormone replacement therapy to address hormonal imbalances at any stage of life, peptide therapies like Sermorelin and NAD+ for energy, recovery, and anti-aging support, erectile dysfunction treatment for men seeking discreet and effective care, and hair loss solutions targeting the underlying hormonal causes of thinning hair
